Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Urine Dipstick Method Developed for Malaria Diagnosis

By LabMedica International staff writers
Posted on 06 Jun 2016
Malaria is the world’s most important tropical parasitic disease and a leading cause of death worldwide and the disease is caused by the parasite, Plasmodium species and transmitted to humans by infected mosquitoes.

Symptoms include fever and usually appear 10 to 15 days after someone is bitten by an infected mosquito. More...
While easily treated, proper early diagnosis is critical to successful management, since many diseases in tropical areas of the world are characterized by fever, but left untreated the parasites multiply in the liver and can become life-threatening.

A Nigerian scientist and a team at Johns Hopkins University (Baltimore, MD, USA) have developed a Urine Malaria Test (UMT), currently in clinical validation, is indicated for use in individuals who present with fever suspected of being malaria. The UMT, which licensed with exclusive global rights from Johns Hopkins University, incorporates a novel dipstick technology that is ideal for rapid point-of-need diagnosis of clinical malaria from urine instead of blood, and offers significant advantages over microscopy and other malaria diagnostics, which require the use of blood.

The UMT dipstick detects novel Plasmodium proteins shed in the urine of febrile malaria patients and can be performed and read by persons with little or no training. These novel proteins or fragments are not cleaved by any known proteases, are highly immunogenic and elicit early immune response, and thus present as early markers of clinical malaria. The UMT is a sensitive and specific immunochromatographic lateral flow assay, which can be easily performed by an untrained individual using a urine sample.

To perform, the test strip is dropped into a clean container with as little as 100 µL of urine, allowed to flow up the strip for 1 to 2 minutes, and incubated at room temperature for 20 minutes. If two visible lines appear on the strip, the test is positive; if one line appears, the test is negative. The UMT demonstrates equivalent performance compared to commercially available blood-based rapid tests for the diagnosis of clinical malaria, with a limit of detection of 125 parasites/µl, well within the 100 to 200 parasites/µl analytical performance range recommended for malaria rapid diagnostic tests by the World Health Organization (Geneva, Switzerland). The UMT is being manufactured by Fyodor Biotechnologies, Inc (Baltimore, MD, USA).

Related Links:
Johns Hopkins University
World Health Organization
Fyodor Biotechnologies

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Hematology Consumables
Bioblood Devices
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.